Literature DB >> 11830448

Remission of Behçet's syndrome with TNFalpha blocking treatment.

M Rozenbaum, I Rosner, E Portnoy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11830448      PMCID： PMC1754029          DOI： 10.1136/ard.61.3.283-a

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; C E Antoni; J W J Bijlsma; G R Burmester; B Cronstein; E C Keystone; A Kavanaugh; L Klareskog
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 2.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; M Dougados; P Emery; A Gibofsky; A F Kavanaugh; E C Keystone; L Klareskog; A S Russell; L B A van de Putte; M H Weisman; A F Kavenaugh
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 5.  Behçet's disease: a new target for anti-tumour necrosis factor treatment.

Authors:  P P Sfikakis
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 6.  Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 7.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 8.  The utility of tumour necrosis factor blockade in orphan diseases.

Authors:  E C Keystone
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

9.  Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.

Authors:  Salvatore Gulli; Carlo Arrigo; Loredana Bocchino; Lucia Morgante; Donatella Sangari; Irene Castagna; Gian Filippo Bagnato
Journal:  BMC Musculoskelet Disord       Date:  2003-08-28       Impact factor: 2.362

Review 10.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.